• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Discov . High-throughput screening of spike variants uncovers the key residues that alter the affinity and antigenicity of SARS-CoV-2

tetano

Editor, Senior Moderator
Cell Discov


. 2023 Apr 11;9(1):40.
doi: 10.1038/s41421-023-00534-2.
High-throughput screening of spike variants uncovers the key residues that alter the affinity and antigenicity of SARS-CoV-2


Yufeng Luo[SUP] #[/SUP][SUP] 1 [/SUP], Shuo Liu[SUP] #[/SUP][SUP] 2 3 [/SUP], Jiguo Xue[SUP] #[/SUP][SUP] 4 [/SUP], Ye Yang[SUP] 1 [/SUP], Junxuan Zhao[SUP] 1 [/SUP], Ying Sun[SUP] 5 [/SUP], Bolun Wang[SUP] 1 [/SUP], Shenyi Yin[SUP] 1 [/SUP], Juan Li[SUP] 1 [/SUP], Yuchao Xia[SUP] 6 7 [/SUP], Feixiang Ge[SUP] 1 [/SUP], Jiqiao Dong[SUP] 6 [/SUP], Lvze Guo[SUP] 6 [/SUP], Buqing Ye[SUP] 1 [/SUP], Weijin Huang[SUP] 3 [/SUP], Youchun Wang[SUP] 8 9 [/SUP], Jianzhong Jeff Xi[SUP] 10 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has elicited a worldwide pandemic since late 2019. There has been ~675 million confirmed coronavirus disease 2019 (COVID-19) cases, leading to more than 6.8 million deaths as of March 1, 2023. Five SARS-CoV-2 variants of concern (VOCs) were tracked as they emerged and were subsequently characterized. However, it is still difficult to predict the next dominant variant due to the rapid evolution of its spike (S) glycoprotein, which affects the binding activity between cellular receptor angiotensin-converting enzyme 2 (ACE2) and blocks the presenting epitope from humoral monoclonal antibody (mAb) recognition. Here, we established a robust mammalian cell-surface-display platform to study the interactions of S-ACE2 and S-mAb on a large scale. A lentivirus library of S variants was generated via in silico chip synthesis followed by site-directed saturation mutagenesis, after which the enriched candidates were acquired through single-cell fluorescence sorting and analyzed by third-generation DNA sequencing technologies. The mutational landscape provides a blueprint for understanding the key residues of the S protein binding affinity to ACE2 and mAb evasion. It was found that S205F, Y453F, Q493A, Q493M, Q498H, Q498Y, N501F, and N501T showed a 3-12-fold increase in infectivity, of which Y453F, Q493A, and Q498Y exhibited at least a 10-fold resistance to mAbs REGN10933, LY-CoV555, and REGN10987, respectively. These methods for mammalian cells may assist in the precise control of SARS-CoV-2 in the future.
 
Back
Top Bottom